Plasmatherapy in Atypical Hemolytic Uremic Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Plasmatherapy has become empirically first-line treatment in atypical hemolytic uremic syndrome (aHUS), although no prospective controlled trials have been conducted. Patients with mutations that induce complete or partial factor H (FH) quantitative deficiency may be controlled by plasma infusions (PI), but plasma exchanges appear more efficient than PI in patients with mutations that result in a mutant dysfunctional FH in the circulation. Early treatment is crucial. Long-term prophylactic plasmatherapy appears more efficient to prevent end-stage renal disease (ESRD) than plasmatherapy only during relapses. However, the longest follow-up with preserved renal function under plasmatherapy is only 6.5 years. Plasmatherapy does not appear to influence the outcome of aHUS with membrane cofactor protein mutation, and its efficacy in patients with factor I, C3, or factor B mutations is suggested by a few reports. We hope complement blockers will offer patients a better chance to avoid ESRD and provide a better quality of life.

REFERENCES

• 1 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(17) 1676-1687
  CrossrefPubMedGoogle Scholar
• 2 Caprioli J, Noris M, Brioschi S International Registry of Recurrent and Familial HUS/TTP et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.  Blood. 2006;  108(4) 1267-1279
  CrossrefPubMedGoogle Scholar
• 3 Sellier-Leclerc A L, Freméaux-Bacchi V, Dragon-Durey M A French Society of Pediatric Nephrology et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2007;  18(8) 2392-2400
  CrossrefPubMedGoogle Scholar
• 4 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
  CrossrefPubMedGoogle Scholar
• 5 Byrnes J J, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma.  N Engl J Med. 1977;  297(25) 1386-1389
  CrossrefPubMedGoogle Scholar
• 6 Bukowski R M, King J W, Hewlett J S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.  Blood. 1977;  50(3) 413-417
  CrossrefPubMedGoogle Scholar
• 7 Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.  N Engl J Med. 1991;  325(6) 398-403
  CrossrefPubMedGoogle Scholar
• 8 Rock G A, Shumak K H, Buskard N A Canadian Apheresis Study Group et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.  N Engl J Med. 1991;  325(6) 393-397
  CrossrefPubMedGoogle Scholar
• 9 Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial.  J Pediatr. 1988;  112(2) 284-290
  CrossrefPubMedGoogle Scholar
• 10 Loirat C, Sonsino E, Hinglais N, Jais J P, Landais P, Fermanian J. The French Society of Paediatric Nephrology . Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial.  Pediatr Nephrol. 1988;  2(3) 279-285
  CrossrefPubMedGoogle Scholar
• 11 Michael M, Elliott E J, Craig J C, Ridley G, Hodson E M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.  Am J Kidney Dis. 2009;  53(2) 259-272
  CrossrefPubMedGoogle Scholar
• 12 Noris M, Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis.  Nat Rev Nephrol. 2009;  5(4) 186-188
  CrossrefPubMedGoogle Scholar
• 13 Gianviti A, Perna A, Caringella A et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome.  Am J Kidney Dis. 1993;  22(2) 264-266
  CrossrefPubMedGoogle Scholar
• 14 Ruggenenti P, Remuzzi G. Pathophysiology and management of thrombotic microangiopathies.  J Nephrol. 1998;  11(6) 300-310
  PubMedGoogle Scholar
• 15 Eddy A A, Geary D F, Balfe J W, Clark W F, Baumal R. Prolongation of acute renal failure in two patients with hemolytic-uremic syndrome due to excessive plasma infusion therapy.  Pediatr Nephrol. 1989;  3(4) 420-423
  CrossrefPubMedGoogle Scholar
• 16 Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship T H. Challenges in the management of infantile factor H associated hemolytic uremic syndrome.  Pediatr Nephrol. 2004;  19(8) 908-911
  PubMedGoogle Scholar
• 17 Saunders R E, Abarrategui-Garrido C, Frémeaux-Bacchi V et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.  Hum Mutat. 2007;  28(3) 222-234
  CrossrefPubMedGoogle Scholar
• 18 Pichette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Delâge J M. Familial hemolytic-uremic syndrome and homozygous factor H deficiency.  Am J Kidney Dis. 1994;  24(6) 936-941
  PubMedGoogle Scholar
• 19 Ohali M, Shalev H, Schlesinger M et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.  Pediatr Nephrol. 1998;  12(8) 619-624
  CrossrefPubMedGoogle Scholar
• 20 Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency.  J Pediatr. 2001;  138(3) 412-417
  CrossrefPubMedGoogle Scholar
• 21 Nathanson S, Frémeaux-Bacchi V, Deschênes G. Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.  Pediatr Nephrol. 2001;  16(7) 554-556
  CrossrefPubMedGoogle Scholar
• 22 Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. Secondary failure of plasma therapy in factor H deficiency.  Pediatr Nephrol. 2006;  21(11) 1769-1771
  CrossrefPubMedGoogle Scholar
• 23 Licht C, Weyersberg A, Heinen S et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.  Am J Kidney Dis. 2005;  45(2) 415-421
  CrossrefPubMedGoogle Scholar
• 24 Cho H Y, Lee B S, Moon K C, Ha I S, Cheong H I, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate.  Pediatr Nephrol. 2007;  22(6) 874-880
  CrossrefPubMedGoogle Scholar
• 25 Sethi S K, Marie-Agnes D D, Thaker N, Hari P, Bagga A. Hemolytic uremic syndrome due to homozygous factor H deficiency.  Clin Exp Nephrol. 2009;  13(5) 526-530
  CrossrefPubMedGoogle Scholar
• 26 Larakeb A, Leroy S, Frémeaux-Bacchi V et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiency—are there therapeutic consequences?.  Pediatr Nephrol. 2007;  22(11) 1967-1970
  CrossrefPubMedGoogle Scholar
• 27 Stratton J D, Warwicker P. Successful treatment of factor H-related haemolytic uraemic syndrome.  Nephrol Dial Transplant. 2002;  17(4) 684-685
  CrossrefPubMedGoogle Scholar
• 28 Gerber A, Kirchhoff-Moradpour A H, Obieglo S et al. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.  Pediatr Nephrol. 2003;  18(9) 952-955
  CrossrefPubMedGoogle Scholar
• 29 Davin J C, Strain L, Goodship T HJ. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.  Pediatr Nephrol. 2008;  23(9) 1517-1521
  CrossrefPubMedGoogle Scholar
• 30 Lapeyraque A L, Wagner E, Phan V et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.  Pediatr Nephrol. 2008;  23(8) 1363-1366
  CrossrefPubMedGoogle Scholar
• 31 Abarrategui-Garrido C, Melgosa M, Peña-Carrión A et al. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome.  Am J Kidney Dis. 2008;  52(1) 171-180
  CrossrefPubMedGoogle Scholar
• 32 De S, Waters A M, Segal A O, Trautmann A, Harvey E A, Licht C. Severe atypical HUS caused by CFH S1191L—case presentation and review of treatment options.  Pediatr Nephrol. 2010;  25(1) 97-104
  CrossrefPubMedGoogle Scholar
• 33 Ferreira V P, Herbert A P, Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.  J Immunol. 2009;  182(11) 7009-7018
  CrossrefPubMedGoogle Scholar
• 34 Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(4) 345-357
  CrossrefPubMedGoogle Scholar
• 35 Richards A, Kemp E J, Liszewski M K et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2003;  100(22) 12966-12971
  CrossrefPubMedGoogle Scholar
• 36 Noris M, Brioschi S, Caprioli J International Registry of Recurrent and Familial HUS/TTP et al. Familial haemolytic uraemic syndrome and an MCP mutation.  Lancet. 2003;  362(9395) 1542-1547
  CrossrefPubMedGoogle Scholar
• 37 Freméaux-Bacchi V, Moulton E A, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2006;  17(7) 2017-2025
  CrossrefPubMedGoogle Scholar
• 38 Fang C J, Frémeaux-Bacchi V, Liszewski M K et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.  Blood. 2008;  111(2) 624-632
  CrossrefPubMedGoogle Scholar
• 39 Couzi L, Contin-Bordes C, Marliot F et al. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair.  Am J Kidney Dis. 2008;  52(2) e5-e9
  CrossrefPubMedGoogle Scholar
• 40 Davin J C, Buter N, Groothoff J et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome.  Pediatr Nephrol. 2009;  24(9) 1757-1760
  CrossrefPubMedGoogle Scholar
• 41 Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.  J Thromb Haemost. 2007;  5(1) 31-41
  CrossrefPubMedGoogle Scholar
• 42 Frémeaux-Bacchi V, Dragon-Durey M A, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.  J Med Genet. 2004;  41(6) e84
  CrossrefPubMedGoogle Scholar
• 43 Bienaimé F, Dragon-Durey M A, Regnier C H et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome.  Kidney Int. 2010;  77(4) 339-349
  CrossrefPubMedGoogle Scholar
• 44 Kavanagh D, Kemp E J, Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(7) 2150-2155
  CrossrefPubMedGoogle Scholar
• 45 Nilsson S C, Karpman D, Vaziri-Sani F et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.  Mol Immunol. 2007;  44(8) 1835-1844
  CrossrefPubMedGoogle Scholar
• 46 Frémeaux-Bacchi V, Miller E C, Liszewski M K et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.  Blood. 2008;  112(13) 4948-4952
  CrossrefPubMedGoogle Scholar
• 47 Goicoechea de Jorge E, Harris C L, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2007;  104(1) 240-245
  CrossrefPubMedGoogle Scholar
• 48 Roumenina L T, Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.  Blood. 2009;  114(13) 2837-2845
  CrossrefPubMedGoogle Scholar
• 49 Lhotta K, Janecke A R, Scheiring J et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.  Clin J Am Soc Nephrol. 2009;  4(8) 1356-1362
  CrossrefPubMedGoogle Scholar
• 50 Ariceta G, Besbas N, Johnson S European Paediatric Study Group for HUS et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.  Pediatr Nephrol. 2009;  24(4) 687-696
  CrossrefPubMedGoogle Scholar
• 51 Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.  Kidney Int. 2001;  60(3) 831-846
  CrossrefPubMedGoogle Scholar
• 52 Allford S L, Hunt B J, Rose P, Machin S J. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology . Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.  Br J Haematol. 2003;  120(4) 556-573
  CrossrefPubMedGoogle Scholar
• 53 Taylor C M, Machin S, Wigmore S J, Goodship T H. working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society . Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.  Br J Haematol. 2010;  148(1) 37-47
  CrossrefPubMedGoogle Scholar
• 54 Michon B, Moghrabi A, Winikoff R et al. Complications of apheresis in children.  Transfusion. 2007;  47(10) 1837-1842
  CrossrefPubMedGoogle Scholar
• 55 Witt V, Stegmayr B, Ptak J et al. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry.  Transfus Apheresis Sci. 2008;  39(3) 255-260
  CrossrefPubMedGoogle Scholar
• 56 Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.  Am J Transplant. 2009;  9(11) 2644-2645
  CrossrefPubMedGoogle Scholar
• 57 Davin J C, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.  Am J Kidney Dis. 2010;  55(4) 708-711
  CrossrefPubMedGoogle Scholar
• 58 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 542-544
  CrossrefPubMedGoogle Scholar
• 59 Gruppo R A, Rother R P. Eculizumab for congenital atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 544-546
  CrossrefPubMedGoogle Scholar

Chantal LoiratM.D. 

Pediatric Nephrology Department, Hôpital Robert Debré

48 Boulevard Serurier, 75019 Paris, France

Email: chantal.loirat@rdb.aphp.fr